Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 3, pp 259–267 | Cite as

Classical Protein Kinase C: a novel kinase target in breast cancer

  • R. K. Singh
  • S. Kumar
  • M. S. Tomar
  • P. K. Verma
  • S. P. Singh
  • P. K. Gautam
  • A. AcharyaEmail author
Review Article
  • 99 Downloads

Abstract

Classical protein kinase C (cPKC) enzymes are ser/thr protein kinases that have been an important factor in regulating a variety of cellular functions required for both in terms of health and disease. Therefore, precise control of cPKC-mediated signal is necessary for cellular homeostasis; however, their dysregulation leads to the development of several pathophysiological conditions including cancer. In cellular microenvironment, cPKC-mediated signaling is accompanied by multiple molecular mechanisms including phosphorylation, second messenger binding, and scaffold proteins. Functional cPKC interacts with a number of cellular proteins involved in the regulation of multiple biological functions such as cell growth, survival, migration, and adhesion. Further, the role of cPKC varies from cell to cell, substrate to substrate and, therefore, it is plausible to assume that the dysregulation of cPKC activity causes cellular transformation. Currently, there is no sufficient literature available to provide better understating to develop an effective therapeutic regimen to reverse pathophysiological condition caused by functionally dysregulated cPKC. Therefore, in the present review, we have focused on to provide a better and detail information on the various aspects of cPKC such as structure, mode of activation, regulation, and distinct cellular functions useful for the development of an effective therapeutic regimen against the breast cancer.

Keywords

Classical protein kinase C Breast cancer Cell adhesion Cellular microenvironment Estrogen receptor 

Notes

Acknowledgements

We are grateful to the CSIR-UGC, New Delhi for the financial support to RKS for his research work.

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no any conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the author.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. 2000;279:L429–38.Google Scholar
  2. 2.
    Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka YD. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982;257(13):7847–51.Google Scholar
  3. 3.
    Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev. 2008;88:1341–78.Google Scholar
  4. 4.
    Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012;11(12):937–57.Google Scholar
  5. 5.
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.Google Scholar
  6. 6.
    Freeley M, Kelleher D, Long A. Regulation of Protein Kinase C function by phosphorylation on conserved and non-conserved sites. Cell Signal. 2011;23:753–62.Google Scholar
  7. 7.
    Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab. 2010;298:E395–402.Google Scholar
  8. 8.
    Newton AC. Regulation of the ABC kinases by phosphorylation: proteinkinase C as a paradigm. Biochem J. 2003;370:361–71.Google Scholar
  9. 9.
    Parker PJ, Parkinson SJ. AGC protein kinase phosphorylation and protein kinase C. Biochem Soc Trans. 2001;29:860–3.Google Scholar
  10. 10.
    Good LE, Ziegler JA, Parekh WH, Alessi DB, Cohen DR, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science. 1998;281:2042–5.Google Scholar
  11. 11.
    Dutil EM, Toker A, Newton AC. Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr Biol. 1998;8:1366–75.Google Scholar
  12. 12.
    Scott AM, Antal CE, Newton AC. Electrostatic and hydrophobic interactions differentially tune membrane binding kinetics of the C2 domain of protein kinase Cα. J Biol Chem. 2013;288:16905–15.Google Scholar
  13. 13.
    Orr JW, Keranen LM, Newton AC. Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol. J Biol Chem. 1992;267:15263–6.Google Scholar
  14. 14.
    Lin D, Takemoto DJ. Oxidative activation of protein kinase Cγ through the C1 domain: effects on gap junctions. J Biol Chem. 2005;280:13682–93.Google Scholar
  15. 15.
    Lauer J, Banerjee D, Shanks D, Dai H, Gong YX, Prakash O, et al. NMR structure/function relationships of peptides corresponding to the C1B1 region of PKCγ. Protein Pept Lett. 2010;17:1–10.Google Scholar
  16. 16.
    Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: a homolog of the β subunit of G proteins. Proc Natl Acad Sci USA. 1994;91:839–43.Google Scholar
  17. 17.
    Stebbins EG, Mochly-Rosen D. Binding specificity for RACK1 resides in the V5 region of βII protein kinase C. J Biol Chem. 2001;276:29644–50.Google Scholar
  18. 18.
    Ron D, Luo J, Mochly-Rosen D. C2 region-derived peptides inhibit translocation and function of β protein kinase C in vivo. J Biol Chem. 1995;270:24180–7.Google Scholar
  19. 19.
    Chen D, Gould C, Garza R, Gao T, Hampton RY, Newton AC. Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J Biol Chem. 2007;282:33776–87.Google Scholar
  20. 20.
    Luo B, Prescott SM, Topham MK. Association of diacylglycerol kinase ζ with protein kinase Cα: spatial regulation of diacylglycerol signaling. J Cell Biol. 2003;160:929–37.Google Scholar
  21. 21.
    Abrahamsen H, Neill AK, Kannan N, Kruse N, Taylor SS, Jennings PA, et al. Peptidyl-prolyl isomerase Pin1 controls down-regulation of conventional protein kinase C isozymes. J Biol Chem. 2012;287:13262–78.Google Scholar
  22. 22.
    Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol. 1998;18:839–45.Google Scholar
  23. 23.
    Leontieva OV, Black JD. Identification of two distinct pathways of protein kinase Cα down-regulation in intestinal epithelial cells. J Biol Chem. 2004;279:5788–801.Google Scholar
  24. 24.
    Lum MA, Pundt KE, Paluch BE, Black AR, Black JD. Agonist-induced down-regulation of endogenous protein kinase Cα through an endolysosomal mechanism. J Biol Chem. 2013;288:13093–109.Google Scholar
  25. 25.
    Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt–FOXO and PKCα, but not S6K1. Dev Cell. 2006;11:859–71.Google Scholar
  26. 26.
    Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 2000;484:217–23.Google Scholar
  27. 27.
    Nakashima S. Protein kinase Ca (PKCa): regulation and biological function. J Biochem. 2002;132:669–75.Google Scholar
  28. 28.
    Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest. 1995;95:1906–15.Google Scholar
  29. 29.
    Black AR, Black JD. Protein kinase C signaling and cell cycle regulation. Front Immunol. 2013;17(3):423.Google Scholar
  30. 30.
    Black JD. Protein kinase C- mediated regulation of the cell cycle. Front Biosci. 2000;5:D406–23.Google Scholar
  31. 31.
    Soh JW, Lee YS, Weinstein IB. Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells. J Exp Ther Oncol. 2003;3(3):115–26.Google Scholar
  32. 32.
    Gruber JR, Ohno S, Niles RM. Increased expression of protein kinase C α play a key role in retinoic acid induced melanoma differentiation. J Biol Chem. 1992;267:13356–60.Google Scholar
  33. 33.
    Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistant membrane translocation of protein kinase C alpha during 12-O-tetradecanoylphorbol-13-acetate induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ. 1996;7:419–28.Google Scholar
  34. 34.
    Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999;59:2815–9.Google Scholar
  35. 35.
    Mayati A, Moreau A, Le Vée Marc, Stieger B, Denizot C, Parmentier Y, et al. Protein kinases C-mediated regulations of drug transporter activity, localization and expression. Int J Mol Sci. 2017;18:764.Google Scholar
  36. 36.
    Ahmad S, Glazer RI. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 1993;43(6):858–62.Google Scholar
  37. 37.
    Fogh BS, Multhaupt HAB, Couchman JR. Protein kinase C, focal adhesions and the regulation of Cell Migration. J Histochem Cytochem. 2014;62(3):172–84.Google Scholar
  38. 38.
    Dovas A, Yoneda A, Couchman JR. PKCα -dependent activation of Rho A by syndecan-4 during focal adhesion formation. J Cell Sci. 2017;119:2837–46.Google Scholar
  39. 39.
    Wallis S, Lloyd S, Wise I, Ireland G, Fleming TP, Garrod D. The isoform of protein kinase C is involved in signaling the response of desmosomes to wounding in cultured epithelial cells. Mol Bio Cell. 2000;11:1077–92.Google Scholar
  40. 40.
    Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, et al. mTOR directs breast morphogenesis through the PKC-alpha-Rac1 signaling axis. PLoS Genet. 2015;11(7):e1005291.Google Scholar
  41. 41.
    Gomez J, Pitton C, Garcia A, Martinez De Aragon A, Silva A, Rebollo A. The zeta isoform of protein kinase C controls interleukin-2-mediatedproliferation in a murine T cell line: evidence for an additional role of protein kinase C epsilon and beta. Exp Cell Res. 1995;218:105–13.Google Scholar
  42. 42.
    Haiyang LI, Weinstein IB. Protein kinase C β enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 2006;66(23):11399–408.Google Scholar
  43. 43.
    Whitman SP, Civoli F, Daniel LW. Protein kinase C beta II activation by 1-beta—darabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2 alpha downregulation. J Biol Chem. 1997;272(23):481–4.Google Scholar
  44. 44.
    Cao M-Y, Shinjo F, Heinrichs S, Soh J-W, Jongstra-Bilen J, Jongstra J. Inhibition of anti-IgM-induced translocation of protein kinase C beta I inhibits ERK2 activation and increases apoptosis. J Biol Chem. 2001;276(24):506–10.Google Scholar
  45. 45.
    Wallace JA, Pitarresi JR, Sharma N, Palettas M, Cuitiño MC, Steven T, et al. Protein Kinase C beta in the tumor microenvironment promotes mammary tumorigenesis. Front Oncol. 2014;4:87.Google Scholar
  46. 46.
    Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7:659–72.Google Scholar
  47. 47.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnson H, Hastie T, Eisen MB, van de Rijan M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclass with clinical implication. Proc Natl Acad Sci USA. 2001;98:10869–74.Google Scholar
  48. 48.
    Suga K, Sugimoto I, Ito H, Hashimoto E. Down-regulation of protein kinase C-alpha detected in human colorectal cancer. Biochem Mol Biol Int. 1998;44:523–8.Google Scholar
  49. 49.
    von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G, et al. MicroRNA 15a, inversely correlated to PKC alpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol. 2012;180:1787–97.Google Scholar
  50. 50.
    Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74:311–7.Google Scholar
  51. 51.
    Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006;25:3286–95.Google Scholar
  52. 52.
    Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, et al. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis. 2014;35:2254–63.Google Scholar
  53. 53.
    Pham TW, Tonetti DA, Protein kinase C alpha (PKCa) is a novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast cancer. In: proceedings of the 106th annual meeting of the American association for cancer research; 2015.Google Scholar
  54. 54.
    Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest. 1995;95:1906–15.Google Scholar
  55. 55.
    Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in a thymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clin Cancer Res. 2001;7:3156–65.Google Scholar
  56. 56.
    Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, et al. Crosstalk between PKC alpha and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2013;2:e60.Google Scholar
  57. 57.
    Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer. 2003;88:1400–2.Google Scholar
  58. 58.
    Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKC alpha expression is a marker for breast cancer aggressiveness. Mol Cancer. 2010;9:76.Google Scholar
  59. 59.
    Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst. 1994;86:1145–51.Google Scholar
  60. 60.
    Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013;24:347–64.Google Scholar
  61. 61.
    Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS. PKCalpha and ERbeta Are associated with triple-negative breast cancers in African American and Caucasian patients. Int J Breast Cancer. 2012;2012:740353.Google Scholar
  62. 62.
    Pham TND, White BEP, Zhao H, Mortazavi F, Tonetti. DA, et al. Protein kinase C α enhances migration of breast cancer cells through FOXC2- mediated repression of p120-catenin Pham. BMC Cancer. 2017;17:832.Google Scholar
  63. 63.
    Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R, Ceci JD, Evers BM, Thompson EA, Fields AP. Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem. 2003;278:11167–74.Google Scholar
  64. 64.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, et al. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol. 2006;85:597–603.Google Scholar
  65. 65.
    Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs. 2002;20:241–51.Google Scholar
  66. 66.
    Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM, Mochly-Rosen D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008;68:6831–9.Google Scholar
  67. 67.
    Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res. 2001;7:634–40.Google Scholar
  68. 68.
    Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 2006;66:11399–408.Google Scholar
  69. 69.
    Manni A, Buckwalter E, Etindi R, Kunselman S, Rossini A, Mauger D, et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression. Cell Growth Differ. 1996;7:1187–98.Google Scholar
  70. 70.
    Gokmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 2010;124:327–35.Google Scholar
  71. 71.
    Pham Thao ND, Debra A. Tonetti protein kinase C alpha in breast cancer: a focus on endocrine resistant and triple negative breast cancer. J Cancer Biol Res. 2016;4(1):1076.Google Scholar
  72. 72.
    Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets. 2004;4:125–46.Google Scholar
  73. 73.
    Dowling CM, Kiely PA. Targeting protein kinase C downstream of growth factor and adhesion signalling. Cancers (Basel). 2015;7:1271–91.Google Scholar
  74. 74.
    Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–32.Google Scholar
  75. 75.
    Dowling CM, Kiely PA. Targeting protein kinase C downstream of growth factor and adhesion signalling. Cancers (Basel). 2015;7:1271–91.Google Scholar
  76. 76.
    Kheifets V, Mochly-Rosen D. Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Pharmacol Res. 2007;55:467–76.Google Scholar
  77. 77.
    Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D. Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene. 2011;30:323–33.Google Scholar
  78. 78.
    Mahmmoud YA. Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br J Pharmacol. 2007;150:200–8.Google Scholar
  79. 79.
    Deka SJ, Mamdi N, Manna D, Trivedi V. Alkyl cinnamates induce protein kinase C translocation and anticancer activity against breast cancer cells through induction of the mitochondrial pathway of apoptosis. J Breast Cancer. 2016;19(4):358–71.Google Scholar
  80. 80.
    Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, et al. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis. 2014;35:2254–63.Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Immunology lab, Department of Zoology, Institute of ScienceBanaras Hindu UniversityVaranasiIndia
  2. 2.Department of BiochemistryAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations